Showing results (1961-1970 of 2,809) with videos related to
Sort By:
Pageof 281
Emerging Infectious Diseases|May 29, 2014
Short-term malaria reduction by single-dose azithromycin during mass drug administration for trachoma, TanzaniaStephen E Schachterle, George Mtove, Joshua P Levens, et al.Transfusion|March 4, 2025
Management challenge of a rare concomitant platelet glycoprotein IV/CD36 and IIb/IIIa deficiencies: Case illustrationTro Sekayan, Elizabeth S Allen, Patricia Kopko, et al.Jac-Antimicrobial Resistance|January 1, 2024
Clinical, microbiological and genomic characterization of Gram-negative bacteria with dual carbapenemases as identified by rapid molecular testingAmmara Mushtaq, Bremy Alburquerque, Marilyn Chung, et al.Critical Care Medicine|November 5, 1999
Intraoperative evaluation of tissue perfusion in high-risk patients by invasive and noninvasive hemodynamic monitoringW C Shoemaker, D Thangathurai, C C Wo, et al.The Journal of Biological Chemistry|April 19, 2008
Translation regulation by eukaryotic initiation factor-2 kinases in the development of latent cysts in Toxoplasma gondiiJana Narasimhan, Bradley R Joyce, Arunasalam Naguleswaran, et al.Journal of Biomedicine & Biotechnology|April 13, 2012
Detection of target ssDNA using a microfabricated Hall magnetometer with correlated optical readoutSteven M Hira, Khaled Aledealat, Kan-Sheng Chen, et al.Surgery|October 1, 1990
The use of the Jarvik-7 total artificial heart and the Symbion ventricular assist device as a bridge to transplantationR Pifarre, H J Sullivan, A Montoya, et al.The Journal of Trauma|March 4, 2000
Deep vein thrombosis prophylaxis in hip fractures: a comparison of the arteriovenous impulse system and aspirinJ G Kennedy, K E Soffe, B W Rogers, et al.Journal of Clinical Pharmacology|May 1, 1995
Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary diseaseK Bachmann, T J Sullivan, J H Reese, et al.Antiviral Chemistry & Chemotherapy|August 3, 2021
V3-Loop genotypes do not predict maraviroc susceptibility of CCR5-tropic virus or clinical response through week 48 in HIV-1-infected, treatment-experienced persons receiving optimized background regimensM E Lewis, P Simpson, J Mori, et al.Pageof 281